Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Veracyte's Prosigna Breast Risk of Recurrence test received Medicare coverage through Palmetto GBA's MolDX program, effective August 19, 2026. Coverage applies to postmenopausal women with early-stage ER+ breast cancer (stage I or II, 0-3 positive lymph nodes), building on the test's June 2026 U.S. launch.
Key figures
- Us launch
- June 2026
- Eligible population
- postmenopausal women with early-stage ER+ breast cancer, stage I or II with 0-3 positive lymph nodes
- Coverage effective date
- August 19, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.